Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16604283 | 0.88 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL20016216 | 0.87 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL17675306 | 0.85 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL21349103 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL16594545 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL26293792 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PKMTP53 | |
| SCHEMBL26074395 | 0.83 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2PKMALDH1A1 | |
| SCHEMBL17065565 | 0.83 | NPC1 (0.89) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL2176413 | 0.83 | NPC1 (0.89) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL4915077 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2PKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | NPC1 4713/4885RAB9A 1217/4885SMN1; SMN2 2432/4885 |
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | GRIN1, GRIN2A, GRIN2B | NPC1 970/4885RAB9A 727/4885SMN1; SMN2 454/4885 |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | NPC1 970/4885RAB9A 727/4885SMN1; SMN2 454/4885 |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN1, GRIN2A, GRIN2B | NPC1 970/4885RAB9A 727/4885SMN1; SMN2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.